Stage 2: Decreased levels of B12 and metabolic abnormalities such as high homocysteine or methylmalonic acid (MMA) levels
The compounds under review are not FDA-approved and will not become so this summer
+ - It is important to acknowledge that many anonymous online users of BPC-157 report adverse effects, including injection site pain and swelling, joint pain, anxiety, panic attacks, heart palpitations, insomnia, drowsiness, weakness, fatigue, loss of appetite, depression, and anhedonia
and found that they can serve as a solvent for a 10 mM stock solution of cisplatin without affecting its anticancer activity (Fig
Heat exposure Temperatures above 86 degrees Fahrenheit (30 degrees Celsius) accelerate degradation of both the peptide and the B12
Thus, this leads to very short half-lives compared to traditional small-molecule drugs [3]